have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Gilead statement on the @NEJM publication of data from the NIAID study of our investigational antiviral drug to treat COVID-19:

Very well deserved. From the @oNKo_innate team, a huge congratulations to Steven Rosenberg @NIH, a pioneer in immune cell therapy on the @CancerResearch Lloyd J Old award for 2020

Load More...
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
o o
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are